Strategic partnership between Nexelis and CNBE INRS

Clients will be able to use each organization's expertise to accelerate the preclinical development of vaccines and immunotherapies and determine the immunotoxicity of candidate molecules


Nexelis and CNBE (INRS) are pleased to announce a strategic partnership in the area of contractual research in preclinical laboratory animal experimentation and immunological analysis by joining their respective expertise. The new strike force allow us to offer expanded and integrated global contract research services in toxicology, pharmacokinetics and biomarker identification, proof-of-concept studies with many animal models and basic and complex immunoassay services that can be tailored to the needs of clients in the development of candidate molecules. This strategic alliance also provides clients with access to CNBE infrastructure for their preclinical studies with biocontainment level 2 pathogens.

With this agreement, clients (academic, industry and small biotech) will be able to use the expertise of each organization to strengthen their drug, vaccine and immunotherapeutic pipeline.




We do not sell services, we offer solutions...

  • Located in the greater Montréal (Laval)
  • GAP® certified (Good Animal Practice)
  • A CRO specialized in exploratory animal studies
    • Toxicity
    • Innovative pharmacokinetic services (rats, dogs, NHP)
    • Drug-efficacy studies (proof-of-concept)
  • Animal housing available for your own studies
  • 78 multifunctional animal housing rooms (130,000 sq. ft.)
  • Animal biosafety level 2 and 3 suites and studies
  • Fast turnaround and flexibility
  • CCAC and AAALAC International Accrediations

Get a proposal